Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patients Journal Article


Authors: Yahalom, J.; Xu, A. J.; Noy, A.; Lobaugh, S.; Chelius, M.; Chau, K.; Portlock, C.; Hajj, C.; Imber, B. S.; Straus, D. J.; Moskowitz, C. H.; Coleman, M.; Zelenetz, A. D.; Zhang, Z.; Dogan, A.
Article Title: Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patients
Abstract: Treatment options for Helicobacter pylori-independent gastric mucosa-associated lymphoid tissue (MALT) lymphoma (GML) include surgery, immunotherapy, chemotherapy, and radiation therapy (RT). The purpose of this study was to investigate the efficacy and safety of RT and routine endoscopic surveillance, hypothesizing that most patients are curable with RT alone. We queried a single institution database at a tertiary referral cancer center for patients with H pylori-independent GML treated with RT between 1991 and 2017. Response was assessed by follow-up endoscopies (EGDs) starting 10 to 12 weeks post-RT. Computed tomography scans were also part of the follow-up program, and positron emission tomography was added when clinically appropriate. We identified 178 patients (median age, 63 years; range, 25-89 years); 86% had stage I disease, 7% had stage II disease, and 7% had stage IV disease. Median RT dose was 3000 cGy over 20 fractions. Ninety-five percent of patients exhibited complete pathologic response on posttreatment EGD. Two patients experienced grade 3 toxicity, and 2 patients experienced in-field secondary malignancies. Over a median follow-up of 6.2 years, 9.6% experienced local failures, and 11.8% developed distant sites of disease. Five-year and 10-year overall survival were 94% and 79%, respectively, from last date of RT. RT is a highly effective and safe treatment for GML with excellent overall survival and very rare acute or late treatment-related toxicities. Favorable outcomes from this large retrospective sample of patients provide credible and compelling support for RT as standard of care for H pylori-independent GML. © 2021 by The American Society of Hematology
Keywords: adult; aged; survival rate; treatment failure; major clinical study; overall survival; cancer radiotherapy; radiation dose; cancer staging; radiation injury; distant metastasis; patient safety; clinical effectiveness; marginal zone lymphoma; helicobacter infection; stomach lymphoma; human; male; female; priority journal; article
Journal Title: Blood Advances
Volume: 5
Issue: 7
ISSN: 2473-9529
Publisher: American Society of Hematology  
Date Published: 2021-04-13
Start Page: 1830
End Page: 1836
Language: English
DOI: 10.1182/bloodadvances.2020003992
PUBMED: 33787863
PROVIDER: scopus
PMCID: PMC8045489
DOI/URL:
Notes: Article -- Export Date: 1 June 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Zhigang Zhang
    428 Zhang
  2. Joachim Yahalom
    626 Yahalom
  3. Carol Portlock
    204 Portlock
  4. Craig Moskowitz
    407 Moskowitz
  5. Ariela Noy
    353 Noy
  6. Andrew D Zelenetz
    768 Zelenetz
  7. Carla Hajj
    164 Hajj
  8. David J Straus
    356 Straus
  9. Ahmet Dogan
    456 Dogan
  10. Monica Rose Chelius
    16 Chelius
  11. Amy Jia Xu
    66 Xu
  12. Karen Chau
    30 Chau
  13. Brandon Stuart Imber
    215 Imber
  14. Stephanie Marie Lobaugh
    56 Lobaugh